Author

L. Turos-Korgul

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

K. Piwocka· 2 shared A. Klejman· 1 shared A. Kominek· 1 shared D. Mukherjee· 1 shared G. Hoser· 1 shared I. Seferynska· 1 shared J. Guzowski· 1 shared J. Swatler· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

K. Piwocka

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High-throughput formulation of reproducible 3D cancer microenvironments for drug testing in myelogenous leukemia

M. Rudzinska-Radecka, L. Turos-Korgul, D. Mukherjee, P. Podszywalow-Bartnicka, K. Piwocka, J. Guzowski

This paper develops a high-throughput microfluidic system to generate reproducible 3D leukemia microenvironments for drug testing, showing that stroma-leukemia interactions protect cells from drug-induced cytotoxicity.

bioRxiv · Jan 10, 2024 · PreprintCancer Biology

Targeting Integrated Stress Response by ISRIB combined with imatinib attenuates STAT5 signaling and eradicates therapy-resistant Chronic Myeloid Leukemia cells

W. Dudka, G. Hoser, S. S. Mondal, L. Turos-Korgul, J. Swatler, M. Kusio-Kobiałka, M. Wolczyk, A. Klejman, M. Brewinska-Olchowik, A. Kominek, M. Wiech, M. M. Machnicki, I. Seferynska, T. Stoklosa, K. Piwocka

This study shows that combining ISRIB with imatinib reduces STAT5 signaling and eliminates imatinib-resistant CML cells by altering transcriptomic profiles.

bioRxiv · May 5, 2021 · PreprintCancer Biology